Sanjeev
Khindri, MB, ChB
Chief Development Officer
Sanjeev Khindri, MB, ChB, joined Liquidia in 2025 where he serves as Chief Development Officer. In this role, Sanjeev leads and supports the company's development programs in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). He brings over 17 years of clinical development experience working across all phases of development from first-in-man to pivotal registrational, working in asthma, chronic obstructive pulmonary disorder (COPD), idiopathic pulmonary fibrosis (IPF), PAH and a number of rare and ultra-rare conditions as lymphangioleiomyomatosis (LAM), myelofibrosis and activated phosphoinositide 3-kinase delta syndrome (APDS). Sanjeev has taken a number of drugs to market in pediatric asthma and COPD. Prior to joining Liquidia, Sanjeev served as EVP Executive Vice President, Clinical Development for Aerovate Therapeutics where he led a large, complex, global Phase 2 study in adult patients with PAH. Prior to Aerovate, he held increasingly senior roles in clinical development across a number of both large and small pharmaceutical companies, including Novartis, GSK, Janssen and Galecto. He Sanjeev has authored more than 25 peer-reviewed publications with scientific interests including COPD, pediatric asthma and IPF. Sanjeev He holds a degree in medicine from the University of Liverpool, UK. He Sanjeev completed his residency in Internal Medicine in Liverpool and specialty training in clinical pharmacology and toxicology from King's College, London, UK and was in full-time clinical practice in acute and general medicine for 12 years.
Sanjeev Khindri, MB, ChB, joined Liquidia in 2025 where he serves as Chief Development Officer. In this role, Sanjeev leads and supports the company's development programs in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). He brings over 17 years of clinical development experience working across all phases of development from first-in-man to pivotal registrational, working in asthma, chronic obstructive pulmonary disorder (COPD), idiopathic pulmonary fibrosis (IPF), PAH and a number of rare and ultra-rare conditions as lymphangioleiomyomatosis (LAM), myelofibrosis and activated phosphoinositide 3-kinase delta syndrome (APDS). Sanjeev has taken a number of drugs to market in pediatric asthma and COPD. Prior to joining Liquidia, Sanjeev served as EVP Executive Vice President, Clinical Development for Aerovate Therapeutics where he led a large, complex, global Phase 2 study in adult patients with PAH. Prior to Aerovate, he held increasingly senior roles in clinical development across a number of both large and small pharmaceutical companies, including Novartis, GSK, Janssen and Galecto. He Sanjeev has authored more than 25 peer-reviewed publications with scientific interests including COPD, pediatric asthma and IPF. Sanjeev He holds a degree in medicine from the University of Liverpool, UK. He Sanjeev completed his residency in Internal Medicine in Liverpool and specialty training in clinical pharmacology and toxicology from King's College, London, UK and was in full-time clinical practice in acute and general medicine for 12 years.